Based on the Bone Biologics Corp stock forecast from 0 analysts, the average analyst target price for Bone Biologics Corp is not available over the next 12 months. Bone Biologics Corp’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Bone Biologics Corp is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Bone Biologics Corp’s stock price was USD 0.94. Bone Biologics Corp’s stock price has changed by -18.21% over the past week, -16.02% over the past month and -77.71% over the last year.
No recent analyst target price found for Bone Biologics Corp
No recent average analyst rating found for Bone Biologics Corp
Company Overview Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts. Read Less
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops ...Read More
Frequently Asked Questions About Bone Biologics Corp (BBLG) Stock
Stock Target Advisor's fundamental analysis for Bone Biologics Corp's stock is Slightly Bearish.
Unfortunately we do not have enough data on BBLG's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BBLG's stock to indicate what its average analyst target is.
BBLG stock's Price/Earning ratio is 0.09.
Our analysis grades BBLG stock's Price / Earning ratio at B. This means that BBLG stock's Price/Earning ratio is above 16% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this BBLG may be undervalued for its sector.
The last closing price of BBLG's stock was USD 0.94.
The most recent market capitalization for BBLG is USD 2.83M.
Unfortunately we do not have enough analyst data on BBLG's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Bone Biologics Corp's stock.
As per our most recent records Bone Biologics Corp has 2 Employees.
Bone Biologics Corp's registered address is 2 Burlington Woods Drive, Burlington, MA, United States, 01803.
You can get more information about it from Bone Biologics Corp's website at https://www.bonebiologics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Bone Biologics Corp (BBLG) Stock
Stock Target Advisor's fundamental analysis for Bone Biologics Corp's stock is Slightly Bearish.
Unfortunately we do not have enough data on BBLG's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BBLG's stock to indicate what its average analyst target is.
BBLG stock's Price/Earning ratio is 0.09.
Our analysis grades BBLG stock's Price / Earning ratio at B. This means that BBLG stock's Price/Earning ratio is above 16% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this BBLG may be undervalued for its sector.
The last closing price of BBLG's stock was USD 0.94.
The most recent market capitalization for BBLG is USD 2.83M.
Unfortunately we do not have enough analyst data on BBLG's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Bone Biologics Corp's stock.
As per our most recent records Bone Biologics Corp has 2 Employees.
Bone Biologics Corp's registered address is 2 Burlington Woods Drive, Burlington, MA, United States, 01803.
You can get more information about it from Bone Biologics Corp's website at https://www.bonebiologics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BBLG !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
